CDP-choline treatment induces brain plasticity markers expression in experimental animal stroke

Neurochem Int. 2012 Feb;60(3):310-7. doi: 10.1016/j.neuint.2011.12.015. Epub 2011 Dec 30.

Abstract

We investigated the effect of CDP-choline on brain plasticity markers expression in the acute phase of cerebral infarct in an experimental animal model. Male Sprague-Dawley rats were subjected to permanent middle cerebral artery occlusion (pMCAO) and treated or not with CDP-choline (500 mg/kg) daily for 14 days starting 30 min after pMCAO. Functional status was evaluated with Roger's test; lesion volume with magnetic resonance imaging (MRI) and hematoxylin and eosin staining (H&E); cell death with TUNEL; cellular proliferation with BrdU immunohistochemistry; vascular endothelial growth factor (VEGF), synaptophysin, glial fibrillary acidic protein (GFAP) and low-density lipoprotein receptor-related protein (LRP) by immunofluorescence and Western-blot techniques. CDP-choline significantly improved functional recovery and decreased lesion volume on MRI, TUNEL-positive cell number and LRP levels at 14 days. In addition, CDP-choline significantly increased BrdU, VEGF and synaptophysin values and decreased GFAP levels in the peri-infarct zone compared with the infarct group. In conclusion, our data indicate that CDP-choline improved functional recovery after permanent middle cerebral artery occlusion in association with reductions in lesion volume, cell death and LRP expression. In fact, CDP-choline increased cell proliferation, vasculogenesis and synaptophysin levels and reduced GFAP levels in the peri-infarct area of the ischemic stroke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects
  • Biomarkers
  • Blotting, Western
  • Brain Chemistry / drug effects*
  • Brain Ischemia / complications
  • Brain Ischemia / pathology
  • Cell Proliferation / drug effects
  • Cytidine Diphosphate Choline / pharmacology*
  • Glial Fibrillary Acidic Protein / biosynthesis
  • Glial Fibrillary Acidic Protein / genetics
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / pathology
  • Magnetic Resonance Imaging
  • Male
  • Neuronal Plasticity / drug effects*
  • Nootropic Agents / pharmacology*
  • Rats
  • Rats, Sprague-Dawley
  • Stroke / drug therapy*
  • Stroke / metabolism
  • Stroke / pathology
  • Synaptophysin / biosynthesis
  • Synaptophysin / genetics
  • Vascular Endothelial Growth Factor A / biosynthesis
  • Vascular Endothelial Growth Factor A / genetics

Substances

  • Biomarkers
  • Glial Fibrillary Acidic Protein
  • Nootropic Agents
  • Synaptophysin
  • Vascular Endothelial Growth Factor A
  • Cytidine Diphosphate Choline